File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ejphar.2021.174300
- Scopus: eid_2-s2.0-85109168843
- PMID: 34217706
- WOS: WOS:000683037500005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases
Title | Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases |
---|---|
Authors | |
Keywords | Phosphatidylinositol 4-kinase PI4K inhibitors Cancer Virus replication Inflammation |
Issue Date | 2021 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar |
Citation | European Journal of Pharmacology, 2021, v. 907, article no. 174300 How to Cite? |
Abstract | Phosphatidylinositol 4-kinase (PI4K) is a lipid kinase that can catalyze the transfer of phosphate group from ATP to the inositol ring of phosphatidylinositol (PtdIns) resulting in the phosphorylation of PtdIns at 4-OH sites, to generate phosphatidylinositol 4-phosphate (PI4P). Studies on biological functions reveal that PI4K is closely related to the occurrence and development of various inflammatory diseases such as obesity, cancer, viral infections, malaria, Alzheimer's disease, etc. PI4K-related inhibitors have been found to have the effects of inhibiting virus replication, anti-cancer, treating malaria and reducing rejection in organ transplants, among which MMV390048, an anti-malaria drug, has entered phase II clinical trial. This review discusses the classification, structure, distribution and related inhibitors of PI4K and their role in the progression of cancer, viral replication, and other inflammation induced diseases to explore their potential as therapeutic targets. |
Persistent Identifier | http://hdl.handle.net/10722/301238 |
ISSN | 2023 Impact Factor: 4.2 2023 SCImago Journal Rankings: 1.055 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, YP | - |
dc.contributor.author | Mikrani, R | - |
dc.contributor.author | Hu, YF | - |
dc.contributor.author | Baig, MMFA | - |
dc.contributor.author | Abbas, M | - |
dc.contributor.author | Akhtar, F | - |
dc.contributor.author | Xu, M | - |
dc.date.accessioned | 2021-07-27T08:08:09Z | - |
dc.date.available | 2021-07-27T08:08:09Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | European Journal of Pharmacology, 2021, v. 907, article no. 174300 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | http://hdl.handle.net/10722/301238 | - |
dc.description.abstract | Phosphatidylinositol 4-kinase (PI4K) is a lipid kinase that can catalyze the transfer of phosphate group from ATP to the inositol ring of phosphatidylinositol (PtdIns) resulting in the phosphorylation of PtdIns at 4-OH sites, to generate phosphatidylinositol 4-phosphate (PI4P). Studies on biological functions reveal that PI4K is closely related to the occurrence and development of various inflammatory diseases such as obesity, cancer, viral infections, malaria, Alzheimer's disease, etc. PI4K-related inhibitors have been found to have the effects of inhibiting virus replication, anti-cancer, treating malaria and reducing rejection in organ transplants, among which MMV390048, an anti-malaria drug, has entered phase II clinical trial. This review discusses the classification, structure, distribution and related inhibitors of PI4K and their role in the progression of cancer, viral replication, and other inflammation induced diseases to explore their potential as therapeutic targets. | - |
dc.language | eng | - |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar | - |
dc.relation.ispartof | European Journal of Pharmacology | - |
dc.subject | Phosphatidylinositol 4-kinase | - |
dc.subject | PI4K inhibitors | - |
dc.subject | Cancer | - |
dc.subject | Virus replication | - |
dc.subject | Inflammation | - |
dc.title | Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases | - |
dc.type | Article | - |
dc.identifier.email | Baig, MMFA: faran@hku.hk | - |
dc.identifier.authority | Baig, MMFA=rp02755 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ejphar.2021.174300 | - |
dc.identifier.pmid | 34217706 | - |
dc.identifier.scopus | eid_2-s2.0-85109168843 | - |
dc.identifier.hkuros | 323349 | - |
dc.identifier.volume | 907 | - |
dc.identifier.spage | article no. 174300 | - |
dc.identifier.epage | article no. 174300 | - |
dc.identifier.isi | WOS:000683037500005 | - |
dc.publisher.place | Netherlands | - |